Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential cytoreductive chemotherapy followed by reduced-intensity allogeneic stem cell transplantation for high-risk myeloid malignancies
2007-000806-64Phase 4Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Jun 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daunorubicin, cytarabine, fludarabine, cyclophosphamide and methotrexate in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloid diseases, sponsored by Barts Health NHS Trust. Primary endpoint: Overall survival. Started Jun 2007; status: terminated.
02
Drugs
daunorubicincytarabinefludarabinecyclophosphamidemethotrexate
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloid diseases
Beyond the preview
Go deeper on 2007-000806-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000806-64.